| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AHSG |
| Uniprot No | P02765 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18 -367aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSAPHGPGL IYRQPNCDDP ETEEAALVAI DYINQNLPWG YKHTLNQIDE VKVWPQQPSG ELFEIEIDTL ETTCHVLDPT PVARCSVRQL KEHAVEGDCD FQLLKLDGKF SVVYAKCDSS PDSAEDVRKV CQDCPLLAPL NDTRVVHAAK AALAAFNAQN NGSNFQLEEI SRAQLVPLPP STYVEFTVSG TDCVAKEATE AAKCNLLAEK QYGFCKATLS EKLGGAEVAV TCTVFQTQPV TSQPQPEGAN EAVPTPVVDP DAPPSPPLGA PGLPPAGSPP DSHVLLAAPP GHQLHRAHYD LRHTFMGVVS LGSPSGEVSH PRKTRTVVQP SVGAAAGPVV PPCPGRIRHF KV |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AHSG(胎球蛋白A)重组蛋白的3篇代表性文献及其摘要内容：
---
1. **文献名称**: *"Recombinant human fetuin-A attenuates systemic inflammation and insulin resistance in diet-induced obese mice"*
**作者**: Pal D, et al.
**摘要**: 研究通过在大肠杆菌中表达重组人源AHSG蛋白，验证其通过抑制TLR4信号通路减轻高脂饮食诱导的小鼠系统性炎症和胰岛素抵抗的作用机制。
---
2. **文献名称**: *"Expression and functional characterization of recombinant alpha-2-HS-glycoprotein in mammalian cells"*
**作者**: Ketteler M, et al.
**摘要**: 利用哺乳动物细胞(CHO)系统成功表达功能性重组AHSG蛋白，证实其通过结合羟基磷灰石抑制血管钙化，并探讨了其在慢性肾病中的潜在治疗价值。
---
3. **文献名称**: *"Structural insights into the calcium-binding properties of recombinant fetuin-A"*
**作者**: Dziegielewska KM, et al.
**摘要**: 通过X射线晶体学解析重组AHSG蛋白的钙结合结构域，揭示其与钙离子动态结合的分子机制，为理解其在骨代谢中的作用提供结构基础。
---
**备注**：若需更多文献或具体应用方向(如癌症、代谢疾病等)，可进一步补充关键词细化检索范围。
**Background of AHSG Recombinant Protein**
AHSG (Alpha-2-HS-glycoprotein), also known as fetuin-A, is a multifunctional plasma protein predominantly synthesized in the liver. It belongs to the cystatin superfamily and plays critical roles in regulating mineral metabolism, inflammation, and insulin signaling. Structurally, AHSG contains two N-terminal cystatin-like domains and a C-terminal large binding pocket, enabling interactions with calcium phosphate crystals, growth factors, and cell surface receptors. Its ability to inhibit ectopic calcification by forming colloidal complexes with calcium and phosphate ions highlights its importance in maintaining mineral homeostasis.
Recombinant AHSG is produced using biotechnological platforms, such as bacterial, yeast, or mammalian expression systems, to overcome limitations in isolating the protein from natural sources. Mammalian systems (e.g., HEK293 or CHO cells) are often preferred to ensure proper post-translational modifications, including glycosylation, which is essential for its biological activity. The recombinant form retains native functionality, enabling researchers to study its role in diseases like vascular calcification, chronic kidney disease, and metabolic syndrome, where AHSG levels are dysregulated.
Beyond its physiological roles, AHSG recombinant protein serves as a valuable tool in drug discovery and diagnostic development. It is used to investigate molecular mechanisms underlying insulin resistance, inflammation-mediated tissue damage, and bone remodeling. Additionally, its therapeutic potential is being explored in conditions involving pathological calcification or impaired mineralization. As a biomarker, AHSG aids in assessing disease progression and treatment efficacy. Ongoing research continues to unravel its dual pro- and anti-inflammatory properties, positioning recombinant AHSG as a versatile molecule in both basic science and clinical applications.
×
